Guillain - Barr é Syndrome May Be Triggered by SARS - CoV - 2 Infection
During study period, 22 percent with GBS had confirmed or probable SARS - CoV - 2 infection; patients had uniform neurologic features (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 25, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Neurology, Pulmonology, Journal, Source Type: news
COVID-19 could make Guillain-Barre more likely for people at risk for disorder
People with COVID-19 may be at increased risk for developing Guillain-Barre syndrome, a study published Friday by the journal Brain found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 24, 2021 Category: Consumer Health News Source Type: news
COVID-19 a Rare Trigger for Guillain-Barr é Syndrome COVID-19 a Rare Trigger for Guillain-Barr é Syndrome
COVID-19 may precede Guillain-Barr é syndrome in rare cases, but a strong link is not likely, according to new data from an international consortium.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 23, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
Covid may be an occasional trigger of rare Guillain-Barré syndrome
Research of Guillain-Barré syndrome patients in China, France, Greece, Italy, the Netherlands, Spain, Switzerland, and the UK suggests there is a correlation between Covid infection and the condition. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2021 Category: Consumer Health News Source Type: news
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety, eff...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Nerve disorder listed as 'very rare' side effect of AstraZeneca jab
Guillain-Barre Syndrome is a "very rare" side effect, occurring in under one in 10,000 people. The disorder is a nerve inflammation that may cause temporary paralysis and difficulty breathing. (Source: The Economic Times)
Source: The Economic Times - September 10, 2021 Category: Consumer Health News Source Type: news
AstraZeneca's Covid jab can trigger nerve disorder Guillain-Barre syndrome, EU says
The European Medicines Agency said they considered it to be 'at least a reasonable possibility' that the AstraZeneca jab could trigger the condition in 'very rare' cases. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2021 Category: Consumer Health News Source Type: news
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals pre...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Information for healthcare professionals on Guillain-Barr é Syndrome (GBS) following COVID-19 vaccination, PHE (published 20th August 2021)
Guidance includes information on presentation/symptoms of GBS, current UK data and reporting suspected cases following COVID vaccination and how to manage patients with previous history. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 24, 2021 Category: Consumer Health News Source Type: news
Coronavirus disease 2019 (COVID-19) Updates, BMJ Best Practice
1. NICE publishes new guidance on vaccine-induced immune thrombocytopenia and thrombosis. 2. FDA authorises casirivimab/imdevimab for prevention of COVID-19.
3. EMA warns of Guillain-Barre syndrome with Janssen COVID-19 vaccine.
4. EMA authorises use of Moderna COVID-19 vaccine in young people aged 12 to 17 years. 5. CDC warns that vaccinated people with breakthrough infections can spread the Delta variant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news
European PRAC continues review reports of Guillain-Barr é syndrome with Astra Zeneca (Vaxzevria) COVID-19 vaccine, EMA
PRAC continues to analyse data on cases of Guillain-Barr é syndrome following vaccination and has requested the marketing authorisation holder to clarify whether further updates to the product information and the risk management plan are necessary. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news
COVID-19 Vaccine Janssen: Guillain-Barr é syndrome (GBS) listed as a very rare side effect, EMA
The European PRAC has assessed the available information (108 cases reported worldwide, when over 21 million had received the vaccine) and concluded that a causal relationship between Covid-19 Vaccine Janssen and the neurological disorder GBS is possible. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 26, 2021 Category: Consumer Health News Source Type: news
CDC Panel Updates Info on Rare Side Effect After J & J Vaccine CDC Panel Updates Info on Rare Side Effect After J & J Vaccine
The ACIP discussed slightly higher rates of the rare side effect of Guillain-Barr é syndrome after the J&J vaccine, and presented reaffirming evidence of the vaccine ' s effectiveness against variants.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 23, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news
J & J vaccine and Guillain-Barr é syndrome: Information on the FDA warning
Regulators and Yale experts say the benefits of receiving the vaccine still outweigh the risks, citing the rare chance of developing the neurological disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 21, 2021 Category: Universities & Medical Training Source Type: news
What You Need to Know About COVID-19 Booster Shots
Since the U.S. began a massive country-wide vaccination effort against COVID-19 last winter, a majority of adult Americans have been immunized. But now it seems that all of them may need an additional dose next year.
Public health experts including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, stress that studies continue to show that the three vaccines currently authorized in the U.S. protect against COVID-19 disease, including against variants of the virus that are more transmissible. But as effective as the vaccines are, they can’t provide 100% immunity against disease. ...
Source: TIME: Health - July 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
